Dark

LYEL
Lyell Immunopharma, Inc. Common Stock
stock NASDAQ

At Close

May 8, 2025 3:59:57 PM EDT

0.4200USD-0.309%(-0.0010)304,240

0.00Bid 0.00Ask 0.0000Spread

Pre-market

May 9, 2025 8:00:30 AM EDT

0.4221USD-1.379%(-0.0059)400

After-hours

May 8, 2025 4:00:30 PM EDT

0.4280USD+1.134%(+0.0048)1,473

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

04:05PM EST Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific GlobeNewswire Inc

Jan 24, 2022

08:11AM EST Lyell Immunopharma Announces FDA Clearance Of IND For LYL132, A T-Cell Receptor Therapy For Solid Tumors Being Developed In Collaboration With GSK Benzinga

08:00AM EST Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a GlobeNewswire Inc

Jan 6, 2022

10:37AM EST Morgan Stanley Maintains Overweight on Lyell Immunopharma, Lowers Price Target to $20 Benzinga

Jan 5, 2022

11:07AM EST Stocks That Hit 52-Week Lows On Wednesday Benzinga

Jan 4, 2022

04:05PM EST Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 3:00 PM ET. GlobeNewswire Inc

Dec 17, 2021

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

Dec 16, 2021

04:05PM EST Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL797, A CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies For Solid Tumors Benzinga

04:05PM EST Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, GlobeNewswire Inc

Dec 15, 2021

04:10PM EST Lyell Immunopharma Announces cGMP Qualification Of LyFE Manufacturing Center In Advance Of Initiating Clinical Programs Benzinga

04:05PM EST -- Lyells cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programs -- LyFE Manufacturing Center integrates digital data analytics into processes for real-time production monitoring and optimization GlobeNewswire Inc

Dec 2, 2021

04:05PM EST Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of Lyells Board of Directors following the end of a temporary medical leave which was disclosed by the Company on September 30, 2021. GlobeNewswire Inc

Nov 12, 2021

08:00AM EST -- Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline GlobeNewswire Inc

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 8, 2021

04:05PM EDT Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15, at 2:00 PM ET. GlobeNewswire Inc

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 12, 2021

10:19AM EDT UPDATE: Morgan Stanley On Lyell Immunopharma Overweight Initiation: Preclinical Data Has Demonstrated Promise Which Supports The Hypothesis And Concepts In Overcoming The Key Barriers To cell Therapy In Solid Tumors Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2021 Benzinga

07:47AM EDT Morgan Stanley Initiates Coverage On Lyell Immunopharma with Overweight Rating, Announces Price Target of $25 Benzinga

07:44AM EDT B of A Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $25 Benzinga

05:43AM EDT JP Morgan Initiates Coverage On Lyell Immunopharma with Overweight Rating, Announces Price Target of $22 Benzinga

05:06AM EDT Goldman Sachs Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $30 Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jun 17, 2021

12:21PM EDT Lyell Immunopharma Shares Open For Trade At $18.75; IPO Priced At $17/Share Benzinga

12:02PM EDT Lyell Immunopharma Shares Indicating $20 On 818K Shares Benzinga

09:27AM EDT Lyell Immunopharma Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/Share Benzinga

Jun 16, 2021

09:50PM EDT Lyell Immunopharma Announces Pricing of Initial Public Offering GlobeNewswire Inc

.dark-mode .GHj0SZ{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .GHj0SZ{ color: #333333; background-color: white; border: 2px solid #333333; }LYELLyell Immunopharma, Inc. Common Stockstock NASDAQ

LYEL
Lyell Immunopharma, Inc. Common Stock
stock NASDAQ